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development of novel targeted
therapies for treating solid tumors
has necessitated the development of
technology to determine their
efficacy in preclinical animal models.
One such technology that can
non-invasively quantify early
changes in tumor cellularity as a
result of an efficacious therapy is
diffusion MRI. In this overview we
present some theories as to the origin
of diffusion changes as a result of
tumor therapy, a robust
methodology for acquisition of
apparent diffusion coefficient maps
and some applications of
determining therapeutic efficacy in a
variety therapeutic regimens and
animal models.
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MRI · NMR
Introduction
Rodent cancer models have become indispensable in the
discovery and assessment of new anticancer agents [1].
Lead compounds that are identified as having anti-tumor
activity using in vitro screening assays are subsequently
evaluated in vivo using rodent models [2,3]. Rapidly
growing transplantable mouse or human tumor cell lines
grown subcutaneously or orthotopically in syngeneic or
immuno-deficient rodents allow for quantification of tu-
mor growth and treatment response monitoring using cal-
iper, colony-forming efficient assays [4–6] or anatomical
imaging (such as T2-weighted MRI) measurements of tu-
mor volume [7].
These traditional methods provide effective ways in
which to quantify cancer therapeutic efficacy. However,
non-invasive surrogate markers of therapeutic efficacy in
250
animal models are needed for several reasons. Firstly,
there are no clinical equivalent measurements that can
be performed during phase II and III trials to relate clin-
ical efficacy back to those observed in preclinical models.
Biopsies are usually acquired pre-treatment but are rarely
(if at all) acquired during or after therapy. In addition,
traditional radiological response (reduction in tumor vol-
ume) is typically only acquired once, several months af-
ter therapy. This response is a complex result of not only
therapeutic efficacy but also patient and tumor charac-
teristics such as patient age and tumor stage. Therefore
it is almost impossible to relate these clinical outcomes
to anything measured in preclinical animal testing. Sec-
ondly, these radiological and colony-forming assays have
no way of quantifying regional heterogeneity in tumor re-
sponse. Spatial differences in tumor treatment response
can be a confounding problem in clinical and experimen-
tal therapeutics. These can arise from regional differences
in perfusion, chemosensitivity and also nonuniform drug
delivery (e.g. delivery/expression of transgene during gene
therapy). Thirdly, earlier and more sensitive/predictive
methods to determine treatment efficacy during the initial
course of treatment would be extremely valuable for facil-
itating therapeutic protocol planning. Since many thera-
peutic agents such as chemotherapy are frequently given
in fractionated cycles, an early assessment of therapeutic
response during the initial phase of administration would
provide an opportunity to gauge optimum dosage and also
provide feedback related to the optimum dose frequency.
Development of early indicators of treatment response
which could also provide information related to the spa-
tial heterogeneity of the effects of treatment would be of
significant benefit for both experimental and clinical tri-
als. These issues underscore the need for using noninvasive
imaging to facilitate the evaluation of the responsiveness
of experimental tumors in preclinical therapeutic studies.
In this regard, largely untapped potential resides in MRI
methods known to be sensitive to tissue structure at the
cellular level. Such information may be derived via mea-
surement of tissue properties that reflect dynamics in the
microscopic environment.
Since molecular and cellular changes precede macro-
scopic changes in tumor size, it would be ideal to have
an assay that could quantify these changes both in clin-
ical cancer therapeutics and preclinical drug trials. For
the last ten years diffusion MRI has been under active
investigation as a possible surrogate marker of anti-tumor
therapeutic efficacy [8–19]. As depicted in Fig. 1, treat-
ment of tumors may result in damage and/or killing of
cells, thus altering the integrity of cell membranes and
thereby increasing the fractional volume of the intersti-
tial space due to apoptotic body formation and cell loss.
These changes have been shown to increase the diffu-
sion of water in the damaged tumor tissue [14,15,17].
Diffusion of water within tissue can be non-invasively
Fig. 1 Schematic representation of the relationship between change
in tissue cellularity and molecular water mobility measured as an
“apparent diffusion coefficient” (ADC). On the left is the evolution
toward necrosis following an effective therapy. The increases in extra-
cellular space and membrane permeability allow greater water mobil-
ity, as illustrated by distributions of diffusion on the right. (Used with
permission from Ross et al. [10])
quantified as an apparent diffusion coefficient (ADC) by
using diffusion MRI. The diffusion of water within the tu-
mor is often heterogeneous, particularly during therapy,
therefore water diffusion within the tumor is often repre-
sented by an ADC histogram, as shown in Fig. 1. ADC is
negatively correlated with tumor cell density, as shown in
Fig. 2; therefore shifts in these ADC histograms to higher
ADC values can be an early and quantifiable indicator of
therapeutic efficacy. One additional advantage of measur-
ing ADC is that it is independent of magnetic field strength
and is a biophysical property of the tissue itself therefore
making it much more comparable from scanner to scanner
than most other MR properties.
Initial studies using diffusion MRI to detect changes
in water diffusion in animal tumor models following high-
dose chemotherapy were found to be very promising [8,
15,19]. Changes in ADC values were observed to precede
changes in tumor growth kinetics and tumor regression,
indicating the potential for applying this approach to early
predictive monitoring of cancer therapy. In addition there
have now been several clinical studies that have shown
correlations between early increases in ADC and tumor
response to therapy [10,14,20–22].
There is tremendous potential for diffusion MRI to
become an important surrogate biomarker for cancer
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Fig. 2 H and E stained histology slides (a) showing decreasing cel-
lularity 9L tumors following treatment with a 13.3 mg/kg dose of
BCNU (b). Changes in mean tumor ADC correlated with these his-
tological changes (c). (Used with permission of Chenevert et al. [14])
therapeutic efficacy. Further clinical and preclinical stud-
ies are underway to evaluate the universality of ADC
response to therapeutic efficacy. ADC imaging of animal
tumor models with standard therapies can help further to
refine and validate ADC imaging as a surrogate marker.
In addition imaging of experimental therapeutic regimens
will also aid in extending its utility into these new ‘molec-
ularly targeted’ therapeutic approaches.
In this paper, an overview of the use of diffusion MRI
as a surrogate marker for evaluating cancer therapeu-
tic efficacy in animal models is presented. This will pro-
vide some examples and strategies of quantifying ADC
changes and evaluating how these relate to cancer thera-
peutic efficacy.
The diffusion pulse sequence
Perhaps the single greatest challenge in the implementa-
tion of diffusion imaging is to acquire quantitative diffu-
sion-weighted images in the presence of physiological mo-
tion that are free from artifacts. While diffusion echo pla-
nar imaging (EPI) has revolutionized clinical diffusion
MRI, diffusion MRI of animal models remains problem-
atic. EPI on higher field (7 T and above) animal MRI scan-
ners can be complicated due to issues such as shortened
tissue transverse relaxation and the requirement for higher
resolution. For this reason conventional, spin-echo-based
methods are usually preferred.
In order to achieve artifact-free longitudinal diffusion
imaging of rodent cancer models in a high-throughput
environment, a practical yet robust diffusion pulse se-
quence and protocol is needed. This strategy must be able
to acquire high-resolution multi-slice diffusion data within
a reasonable time frame (10–20 min), with minimal animal
preparation and with minimal motion artifacts. Presented
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here is a practical diffusion pulse sequence (Fig. 3)
and protocol that has been designed for routine ‘high-
throughput’ imaging of animal models. The pulse
Fig. 3 a Gradient waveform for isotropic diffusion weighting, flow
compensation and navigator echo. Gx is the read gradient direction,
Gy is the phase-encoding direction and Gz is the slice direction. Diffu-
sion gradients on all three gradient directions contribute to the overall
“b value”. b Plot of b values as a function of time during diffusion
pulse sequence. c Plot of k-space “first moments” as a function of
time during the diffusion pulse sequence
sequence and reconstruction methodology combines the
previously developed concepts of spin echo multi-slice
imaging, isotropic diffusion weighting [23,24], first mo-
ment motion and flow compensation [25], and naviga-
tor echo correction [26] to produce, high signal-to-noise
and high-resolution apparent diffusion coefficient images
while requiring only minimal animal preparation and
shimming; it is also insensitive to bulk translational and
rotational motion due to the animal respiratory cycle.
Monitoring the diffusion of water using MRI can be
accomplished by making the MR signal intensity depen-
dent on water mobility by the application of additional
pulsed magnetic field gradients incorporated within the
normal MRI sequence [27]. Individual nuclear spins of the
tumor water molecules accumulate a phase shift in propor-
tion to their spatial position in these additional gradient
fields. After waiting a given evolution time for spins to dif-
fuse, a second gradient pulse is applied to completely refo-
cus or re-phase stationary spins. However water molecules
that have diffused during this evolution time do not expe-
rience the same magnitude of phase shift and are therefore
refocused incompletely. Thus, the paired gradient pulses
attenuate signal in proportion to local tissue water mobil-














S is the diffusion-weighted signal, S0 is the intrinsic MR
signal, δ is the duration of the diffusion-encoding gradient
pulses,  is the time between the diffusion gradients, γ is
the gyro-magnetic ratio and G is the diffusion-encoding
gradient amplitude. Quantitative measurements of diffu-
sion coefficient (ADC) values are obtained by measur-
ing signal attenuation as a function of varying gradient
strength and evolution time. In many tissues (including
brain) the diffusion of water is anisotropic, i.e., the rate
of diffusion is more or less restricted depending on the
direction of the diffusion gradients (G) relative to the
underlying cellular structure. For measuring changes in
the underlying tumor morphology the rotationally invari-
ant mean ADC needs to be measured. This can be achieved
in two ways. Firstly and most simply one can measure
ADC using three different gradient sensitizations that are
orthogonal to each other (e.g. Gx , Gy , Gz), such that ADC







This has the disadvantage that it requires at least four
images to be acquired to calculate ADCav. While this
is unproblematic in clinical echo planar imaging where
the images only take seconds to acquire, in animal
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imaging studies when spin-echo-based sequences are used
the acquisition of two extra images can increase scan times
by the order of 20 min.
One way to reduce the scan time is to change the direc-
tion of the diffusion sensitization gradients during the
diffusion period (Fig. 1) such that the diffusion weight-
ing is equally applied in three orthogonal directions.
In the case of a generalized waveform of diffusion sen-
sitization the following applies:








k(t ′)T · k(t ′)dt ′ =













=b0{ADCxx +ADCyy +ADCzz} (5)
Equation (5) then, is essentially a rotationally invariant
form of the Stjeskal–Tanner equation (1) where the rota-
tionally invariant ADC value is given by Eq. (3). From
Eqs. (4) and (5) it is necessary to note that, to achieve iso-
tropic diffusion weighting in a single scan, the waveform
of the applied magnetic field gradients must be such that
the diagonals of the ‘b-matrix’ are equal and the off-diag-
onals are as close to zero as possible [23]. Figure 3b shows
the evolution of the elements of the ‘b-matrix’ during the
diffusion pulse sequence shown in Fig. 3a. Note that at
the echo center the diagonal elements of the matrix b are
essentially equal while the off-diagonals are minimized.
As discussed above motion artifacts present a signifi-
cant problem in spin echo diffusion imaging sequences.
This generally presents itself as large ghosting artifacts
in the phase-encoding direction (Fig. 4a). The pulse
sequence in Fig. 3a has two methods for reducing these
phase-encode artifacts. Firstly, the gradient waveforms
were further constrained such that the “first moments”
of the gradient waveforms are minimized at the imaging
echo center (Fig. 3c). Secondly a 32-point non-phase-
encoded echo (navigator echo) is acquired before the imag-
ing echo is acquired. Using this echo it is possible to correct
any phase-encode errors during image reconstruction [26]
to produce diffusion-weighted images and corresponding
ADC maps (Fig. 4b and c) with minimal artifacts.
Imaging protocol
In general for the examples presented in this review mul-
tiple 1-mm slices were acquired with a 0.5-mm gap and a
Fig. 4 Diffusion-weighted images without (a) and with (b) navigator
echo correction, and corresponding ADC maps of transverse (top)
and coronal (bottom) through a rat brain
3-cm FOV using a standard parallel multi-slice acquisition
scheme on a 7-T Varian MRI scanner. The acquisition
matrix was 128×128 with a 32-point navigator echo that
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Fig. 5 Illustration of a 9L rat glioma treated with a single “low”
dose (6.65 mg/kg) of BCNU chemotherapy. At this low dose, the 9L
model mimics the course of a non-responder because tumor growth
rate is only slightly retarded. Serial T2-weighted MR images (a) of this
animal indicate continued tumor growth. The corresponding ADC
maps are illustrated in column (b), where brighter pixels represent
higher water mobility. The distributions of ADC values within the
tumor are illustrated in column (c) for these three time points. Note,
a slight increase in water diffusion at 6 days after treatment, but the
tumor returns to a dense cellular state by day 11. The area under each
histogram is proportional to tumor volume. (Used with permission
of Ross et al. [10])
was zero filled to 256 × 256. ADC maps were calculated
from two diffusion-weighted data sets with a b value of
1148 s/mm2 and an echo time of 60 ms. Using a recycling
time of 3 s, a NEX of two for the “high b value image”
and a NEX of one for the “low b value image”, the acqui-
sition of the total data set was accomplished in ∼17 min.
Animals were generally anesthetized using 1.5% isoflura-
ne. During imaging animals were free to breathe normally
and were maintained at 37◦C using a water pad connected
to a heated water recirculation unit.
Chemotherapy dose response of ADC
The usefulness of a surrogate marker for therapeutic
efficacy in preclinical animal testing depends on several
key attributes. It must be sensitive enough to measure
modest therapeutic effects yet it must have a significant
dynamic range that it can differentiate between different
levels of therapeutic effect. To demonstrate the utility of
diffusion MRI for distinguishing a relatively ineffective
treatment from an effective treatment, rats with orthotop-
ically implanted gliomas were treated with a single low
dose of BCNU (6.65 mg/kg) and a single high dose of
BCNU (26.6 mg/kg). Data from the animal treated with
the low-dose schedule is shown in Fig. 5. Anatomical
T2-weighted images of the brain are shown before and
at two time points after treatment along with the corre-
sponding ADC maps and tumor ADC histograms. From
the anatomical images, it is clear that the tumor contin-
ued to grow, and no regression of the mass was observed.
The ADC maps of the brain revealed a slight increase
in the tumor signal intensity, which reflects that a small
amount of cell killing had occurred [14]. These changes
were quantified by segmenting the tumor regions from the
ADC maps and plotting a histogram wherein the quantity
of pixels (y-axis) were plotted versus the ADC values (x-
axis) for the entire tumor mass over time. The area under
the histogram curve is proportional to the tumor volume.
As shown in the ADC histograms (Fig. 5), there was a
slight shift to the right (higher mean diffusion values) at
day 6 after treatment, indicating a transient loss of cells
from the tumor mass, which recovered by day 11. For pre-
clinical drug studies, the ability of diffusion MRI to detect
a small therapeutic effect, especially when the anatomical
images were unable to provide any clear evidence of ther-
apeutic benefit, is in fact quite valuable. In this regard,
detection of a therapeutic effect in a limited small num-
ber of animals could be quantified using diffusion MRI,
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Fig. 6 Illustration of a 9L rat glioma treated with a single “high”
dose (26.6 mg/kg) of BCNU chemotherapy. At this high dose, this
rat mimics a responder because tumor shrinks substantially. Serial
T2-weighted MR images of this animal, shown in column (a), illus-
trate the degree of maximal tumor shrinkage on day 21. The corre-
sponding ADC maps are shown in column (b). Despite continued
tumor growth on day 7, the increase water mobility is visually appar-
ent on the ADC maps, which suggests necrosis. This is also illustrated
graphically in the diffusion histograms (c). (Used with permission of
Ross et al. [10])
and the decision could be made to increase the dosage to
determine whether the drug treatment could be improved.
In this brain tumor model system, the dosage of BCNU
was increased fourfold, and the results from the anatom-
ical images, ADC maps, and tumor diffusion histograms
are shown in Fig. 6. This therapeutic dosage of BCNU
resulted in a significant regression of the tumor mass, as
observed on day 21 after treatment. A large increase in tu-
mor diffusion values was observed at day 7 as evidenced by
the bright tumor signal intensity in the ADC maps as com-
pared with the pretreatment image. It is also important to
note that the change in tumor diffusion values preceded
regression, indicating that diffusion MRI can detect early
therapeutic-induced changes to the tumor. Comparison
of the histogram changes of the tumor treated with the
high BCNU dose (Fig. 6) with the animal treated with the
low dose (Fig. 5) revealed that the magnitude of the diffu-
sion increase varied with therapeutic outcome. Although
Figs. 5 and 6 demonstrate isolated examples, the results
are quite reproducible in larger cohorts of animals [14].
Results published previously [14] demonstrate that the low
dose achieves relatively little to no therapeutic efficacy (0.2
log cell kill) and only modest but significant increase in
ADC (∼10%) 4 days after chemotherapy. In contrast the
high-dose schedule had on average a much larger and sig-
nificant increase in ADC (∼30%) that correlated with a
much larger cell kill (∼2.0 [7]).
ADC imaging of subcutaneous tumor models
Another example that demonstrates the robustness of
the use of diffusion MRI is provided from a study of
a subcutaneous PC-3 (prostate) tumor grown in a nude
mouse which was treated with 100 mg/kg (i.p.) Campto-
sar. As shown in Fig. 7, the diffusion increased signifi-
cantly following treatment, which also corresponded to
a dramatic reduction (loss) of tumor growth versus the
untreated (control) animal. Although the efficacy of Cam-
ptosar in treating PC-3 tumors can be assessed by the vol-
ume response, this is not the case when using orthotopic
models or in clinical practice. The early diffusion response
shows that ADC imaging has the potential to serve as an
early surrogate marker of Camptosar therapeutic efficacy
both in orthotopic models and in the clinical management
of prostate cancer.
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Fig. 7 Diffusion-weighted MRI study of a subcutaneous PC-3 (pros-
tate) tumor in a nude mouse treated with 100 mg/kg (i.p.) Camptosar
(unpublished data). a The three-grayscale anatomical T2-weighted
images are overlaid with a diffusion map (color) of the tumor, from
left to right (day 3, day 12 and day 29 post-treatment). Note the
increase in tumor diffusion values (blue) on day 12 post-treatment.
Tumor data is also displayed in histogram format over time (b) from
the same animal as the images. The plot of “Mean relative ADC
change (%)” versus time is the change in Mean ADC relative to day 0
of three treated and three control animals c. Solid symbols are ADC
(circle=treated, square=control) and open symbols are volume (cir-
cle=treated, square=control)
ADC imaging of gene therapy
The flexibility of diffusion MRI in preclinical animal
studies is evidenced by a recent study of two gene therapy
regimens [29]. The use of a yeast cytosine deaminase trans-
gene to convert the relatively innocuous 5-fluro-cytosine
(5FC) to the cytotoxic 5-fluro-uracil (5FU) is one of the
potential candidates for gene therapy of brain tumors.
In this recent study two different transgenes for the con-
version were constructed and evaluated for the therapeu-
tic efficacy. The first (yCD transgene) relies on wild-type
expression of UPRT to help convert 5FC to 5FU while the
second (yCD-UPRT) has the UPRT protein fused to the
yCD transgene. Figure 8 shows the results for three differ-
ent 9L stable cell lines grown as orthotopic tumors: a wild-
type 9L tumor, a tumor expressing the yCD transgene
and another expressing the yCD-UPRT transgene. The
animals with transgene tumors were treated with 1 g/kg
of 5FC for ten consecutive days while the animals with
wild-type 9L tumors were treated with vehicle only. Fig-
ures 8a, b and c show that the two therapies are clearly
different. Both the animals containing transgene 9L tu-
mors showed significant tumor regression and increased
ADC. However, the increase in ADC within the yCD-
UPRT tumors was markedly increased over the yCD tu-
mor. These results were corroborated by those of a larger
cohort of animals (Fig. 8d–f). It was found that, although
tumor volume (Fig. 8d) showed no differences between
the yCD and yCD-UPRT transgenes, the ADC changes
were significantly higher in the yCD-UPRT tumors from
days 7 through 15 (Fig. 8e). This higher ADC change cor-
responded to a much-improved animal survival rate of the
yCD-UPRT therapy over yCD (Fig. 8f).
Diffusion heterogeneity
One final application of the use of ADC imaging as a sur-
rogate marker of therapeutic efficacy that has yet to be
investigated fully but was alluded to in a recent report
[30] is the use ADC imaging to quantify heterogeneity of
response. Figure 9 shows how diffusion is effective at iden-
tifying regions that show a poor response to therapy. In
this case a rat bearing a 9L tumor had a highly effective
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Fig. 8 Individual T2-weighted coronal MRI through the largest
cross section of tumor acquired at the first day of treatment (day
1) and serially afterward. The map of apparent diffusion coefficients
is overlaid in a color wash with blue representing low diffusion and
red high diffusion. Wild-type 9L tumor (a) treated with PBS. CD
expressing (b) or CD-UPRT expressing (c) treated with daily 5FC
(1,000 mg/kg for 10 days). Tumor volume (d) and relative ADC val-
ues (e) as a function of time post treatment for wild-type 9L tumors
treated with PBS (closed triangles) or for CD-expressing (closed cir-
cles) or CD-UPRT expressing (open circles) 9L tumors treated with
5FC (1,000 mg/kg i.p. daily for 10 days starting at day 1). Data repre-
sent the mean and standard error for wild-type (n=6), CD-expressing
(n=3), and CD-UPRT expressing (n=6) tumors. Kaplan–Meier sur-
vival curve (f) for animals as a function of time since implantation for
wild-type 9L tumors treated with PBS (single dashed line, n= 6) or
for CD-expressing (broken dashed line, n=3) or CD-UPRT express-
ing (solid line, n= 64) 9L tumors treated with 5FC (1000 mg/kg i.p.
daily for 10 days starting at day 17 post implantation). (Used with
permission of Hamstra et al. [29])
dose of BCNU injected directly into the tumor (DTI-015,
Direct Therapeutics Inc.). However, it is clear on the diffu-
sion overlays (Fig. 9a) that there is a small region at the
base of the tumor that does not increase in ADC nearly
as much as the bulk of the tumor (Fig. 9b). Although the
tumor shrinks considerably, tumor cells within this small
tumor focus where shown by diffusion MRI to have not
been effectively treated and in fact served as the seed for
tumor regrowth.
Discussion
In this review we have shown evidence that diffusion MRI
in animal models can provide important information not
only in understanding how to translate diffusion as a sur-
rogate marker into the clinic, but also to gain important
information with regards to dose escalation in preclinical
drug-discovery experiments. It has also been shown that
diffusion MRI provides a robust surrogate that can be
used to investigate gene therapy and chemotherapy regi-
mens in both subcutaneous and orthotopic tumor models.
For preclinical drug studies using orthotopic animal
tumor models, animal survival or animal morbidity are
traditional therapeutic endpoints for quantification of
treatment efficacy. The use of diffusion MRI offers a sig-
nificant improvement over these traditional approaches
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Fig. 9 Diffusion study of direct injection of BCNU (DTI-015, Direct
Therapeutics, unpublished data). Panel A represents individual T2-
weighted coronal MRI through the largest cross section of tumor
for the animal treated with DTI-015 which subsequently was docu-
mented to have recurrence. Images were acquired prior to treatment
(pre-) and serially afterward. The map of apparent diffusion coeffi-
cients is overlaid in a color wash with blue representing low diffusion
(ADC = 0.5) and red high diffusion (ADC = 2.0). In Panel B the ADC
values for the indicated regions of interest are plotted as a function
of time in days since injection of DTI-015. The large central mass
of tumor is indicated with open circles, and the small ventral medial
lobe of tumor is indicated with closed circles. (Used with permission
of Hall et al. [30])
including the ability to use the same animal as its own
control, greater sensitivity to relatively small therapeutic
effects, the ability to quantify effects of varying the drug
dosage and timing, and finally, the potential of requiring
smaller numbers of animals to obtain statistical signifi-
cance. This latter issue can be especially important if vari-
ables such as heterogeneity of tumor take or growth rates
are properties of the tumor model used. Another impor-
tant aspect of the use of diffusion MRI is that it is trans-
latable from the animal model into a clinical trial, which
could thus provide a valuable quantitative and sensitive
surrogate marker for therapeutic monitoring. Presently, a
comparison of sequential MRI or computed tomography
scans is the method of choice for monitoring the response
of solid tumors to therapy, which compares the change
in cross-sectional area of the tumor via the product of the
maximal perpendicular tumor diameters or full volume
determination [31,32]. For MRI, gadolinium-enhanced
T1-weighted images are often used, but T2-weighted or
other MR contrast strategies may be used. Comparisons
of tumor burden are usually made between pretreatment
scans and those obtained weeks to months after the con-
clusion of a therapeutic protocol [31,32]. Methods such
as diffusion MRI for assessing treatment response that are
not dependent on relatively slow changes in tumor volume
may be capable of providing earlier indications of ther-
apeutic outcome because molecular and cellular changes
typically precede observable macroscopic changes in gross
tumor size. Therefore, the use of a quantitative MRI surro-
gate marker scheme such as water diffusion for determina-
tion of therapeutic induced changes in tumor cellularity is
an area of active research investigation [14,17,21,22,33].
In conclusion, the ability of ADC to become an ac-
cepted surrogate of therapeutic efficacy will depend not
on its ability to correlate with therapeutic efficacy but on
its ability to predict it. Therefore much effort is needed
to investigate the predictability of ADC imaging. Imaging
ADC changes in preclinical therapeutic investigations will
be vital for understanding just how universal ADC can be
in predicting anti-cancer therapeutic efficacy.
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